← Human Trials & Peer-Reviewed Studies
25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
Plain-language guide to PMID 24135218 (2013): multicenter randomized controlled trial of Vitamin D, K2, Magnesium and Zinc and Angiotensin II in 12 patients.
Key Facts
- PMID
- 24135218
- Journal
- Clinical journal of the American Society of Nephrology : CJASN
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Fernández-Juárez G et al. (9 authors)
- DOI
- 10.2215/CJN.00910113
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc and Angiotensin II in this randomized controlled trial publication.
Patients with type II diabetes and CKD have an exceptionally high rate of severe 25 (OH) vitamin D deficiency; however, it is not known whether this deficiency is a risk factor for progression of diabetic nephropathy.
This study aimed to investigate whether there is an association of 25 (OH) vitamin D deficiency with disease progression in type II diabetic nephropathy.
Who Took Part
The study group was 12 patients.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
All study participants were included in the analysis.
How the Study Was Run
In design terms this was a randomized and multicenter study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.
What Was Measured
PubMed files the paper under topics including Aldosterone, Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Biomarkers, Chi-Square Distribution, Creatinine and Diabetes Mellitus, Type 2.
What This Means in Plain Language
The paper is a randomized and multicenter study of Vitamin D, K2, Magnesium and Zinc and Angiotensin II in 12 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2013 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Angiotensin II compound page, all human trials.
Our Notes on the Compounds
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.